TY - JOUR
T1 - Drug-based therapy for advanced adenoid cystic carcinoma
T2 - Current landscape and challenges based on an overview of registered clinical trials
AU - Wagner, Vivian Petersen
AU - Ferrarotto, Renata
AU - Vargas, Pablo Agustin
AU - Martins, Manoela Domingues
AU - Bingle, Colin D.
AU - Bingle, Lynne
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2023/1
Y1 - 2023/1
N2 - Adenoid cystic carcinoma (ACC) has a significant patient-population in need of effective systemic therapy, as no drug is currently approved by the FDA for its management. We critically reviewed ACC-clinical trials (CT) registered on the ClinicalTrials.gov website using “ACC” under condition or disease. Trials specifically designed to test a drug-based therapy for ACC (n = 33) were analyzed with most being one-arm phase II trials enrolling advanced, recurrent/metastatic, incurable ACC cases. Site restriction, maximum ECOG status, and period of disease progression varied as inclusion criteria. Small-molecule inhibitors were those most commonly investigated with Apatinib, Axitinib and Lenvatinib showing the best results in association with rigid enrollment criteria. The overall median time to progression remains modest and more efforts are urgently needed in this field. CTs designed to test drugs that act on key pathways associated with ACC aggressiveness are being conducted and represent a promising pathway if efficacy is proved.
AB - Adenoid cystic carcinoma (ACC) has a significant patient-population in need of effective systemic therapy, as no drug is currently approved by the FDA for its management. We critically reviewed ACC-clinical trials (CT) registered on the ClinicalTrials.gov website using “ACC” under condition or disease. Trials specifically designed to test a drug-based therapy for ACC (n = 33) were analyzed with most being one-arm phase II trials enrolling advanced, recurrent/metastatic, incurable ACC cases. Site restriction, maximum ECOG status, and period of disease progression varied as inclusion criteria. Small-molecule inhibitors were those most commonly investigated with Apatinib, Axitinib and Lenvatinib showing the best results in association with rigid enrollment criteria. The overall median time to progression remains modest and more efforts are urgently needed in this field. CTs designed to test drugs that act on key pathways associated with ACC aggressiveness are being conducted and represent a promising pathway if efficacy is proved.
KW - Chemotherapy
KW - Head and neck cancer
KW - Oncology
KW - Salivary gland cancer
UR - http://www.scopus.com/inward/record.url?scp=85144056326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144056326&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2022.103886
DO - 10.1016/j.critrevonc.2022.103886
M3 - Review article
C2 - 36427771
AN - SCOPUS:85144056326
SN - 1040-8428
VL - 181
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103886
ER -